Current Understanding of Pathogenesis and Therapeutic Advancements in Diabetes Mellitus: Focus on New Drug Development and Clinical Evaluation

Abstract

This review examines the current understanding of diabetes mellitus pathogenesis and evaluates how this mechanistic knowledge is translating into new drug development and clinical evaluation, with the specific aim of mapping the pathway from disease biology to emerging therapeutic strategy. Diabetes mellitus comprises several clinically distinct subtypes, principally Type 1, Type 2, gestational diabetes, and monogenic forms such as maturity-onset diabetes of the young, which share overlapping yet mechanistically distinct drivers: β-cell dysfunction, insulin resistance in metabolic tissues, chronic low-grade inflammation, oxidative and endoplasmic reticulum stress, gut microbiome alterations, and genetic and epigenetic influences. Rather than cataloguing individual agents, this review classifies emerging interventions into four broad categories, lifestyle and metabolic interventions, pharmacological agents targeting glycemic and cardiorenal outcomes, technology-enabled glucose management, and regenerative and immune-based approaches, and assesses their combined contribution to disease control, distinguishing this synthesis from prior narrative overviews of diabetes therapeutics. Lifestyle interventions, including dietary modification, structured exercise, and, where indicated, metabolic surgery, remain foundational because they act directly on the insulin resistance and energy-balance mechanisms underlying Type 2 diabetes, and no pharmacological therapy fully substitutes for their effect. Pharmacological advances, including GLP-1 receptor agonists, SGLT2 inhibitors, and dual incretin agonists, now provide glycemic control alongside demonstrated cardiovascular and renal protection. Continuous glucose monitoring and closed-loop insulin delivery systems have improved real-time glycemic management, while nanotechnology-based drug delivery, gene therapy, and stem cell-derived β-cell replacement constitute early-stage but mechanistically grounded strategies for restoring physiological glucose homeostasis. Across these categories, common limitations persist, including incomplete β-cell preservation, variable sustainability of weight loss, delayed diagnosis, unequal access to advanced therapies, and unresolved ethical and regulatory questions. Durable disease control will therefore depend on integrating mechanistic, pharmacological, and regenerative strategies within personalized, biomarker-guided treatment frameworks supported by equitable healthcare delivery.